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The main objective of this review article is to overcome or to improve the problems related with curcumin 
with the help of new technologies or modifications to make a promising therapeutic agent which gives a good 
therapeutic response. Curcumin, a known natural polyphenolic compound obtained from dietary spice 
turmeric, possesses pharmacologic effects including anti-inflammatory, antioxidant, and many other 
activities. Clinical trials   on curcumin have shown its safety and efficacy even at high doses in humans. But 
inspite of that it shows poor bioavailability (oral bioavailability) which is one of the major problems 
regarding curcumin. There are other reasons contributing to the low plasma and tissue levels of curcumin 
appear to be due to poor absorption, rapid metabolism, and rapid systemic elimination. To improve the 
bioavailability of curcumin, numbers of approaches have been undertaken. These approaches involve, first, 
the use of adjuvant like piperine that interferes with glucuronidation; second, the use of liposomal curcumin; 
third, curcumin nanoparticles; fourth, the use of curcumin phospholipids complex; and fifth, the use of 
structural analogues of curcumin.  
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INTRODUCTION 
Phytochemicals a naturally occurring substance 
obtained from plants. There has been wide use of 
phytochemicals which is obtained from nutritional 
component to heal human diseases [1, 2]. Curcumin 
(Curcuma longa) an active ingredient of a much known 
spice ,turmeric, used in cooking in whole India and also 
other regions of Asia[3, 4] which belongs to ginger family 
(Zingiberaceae)[5] having number of pharmacological 
effects including anti-inflammatory, antioxidant, anti 
proliferative and antiangiogenic activities. 
Commercially curcumin contains approximately 77% 
diferuloylmethane, 17% demethoxycurcumin, and 6% 
bisdemethoxycurcumin. [6, 7] 
 
CHEMISTRY 
Curcumins are polyphenols responsible for yellow 
color. Curcumin have several functional groups. 
Polyphenols are attached with two alpha and beta 
unsaturated carbonyl group which forms an aromatic 
ring. The two carbonyl groups form a diketone. The 
diketone form stable enols or are easily deprotonated 
and form enolates, while the alpha, beta-unsaturated 
carbonyl undergoes nucleophilic addition [5]. Curcumin 
is unstable at basic pH, and degrades in 30 min to 
Trans-6-(40-hydroxy-30-methoxyphenyl)-2, 4- dioxo-5-
hexanal, ferulic acid, feruloylmethane and vanillin [8, 9]. 
The presence of foetal calf serum or human blood, or 
addition of antioxidants such as ascorbic acid, N-
acetylcysteine or glutathione completely blocks the 
degradation in culture media or phosphate buffer above 
pH 7. Under acidic conditions, the degradation of 
curcumin is much slower, with less than 20% of total 
curcumin decomposed at 1 h. [8, 10]   
 
PHARMACOLOGICAL ACTIVITIES 
Inflammation
 [12] 
Curcumin inhibits the enzyme which is related to 
activation of inflammatory substances. Curcumin shows 
natural anti inflammatory activity as same as steroidal 
drugs and some of steroidal drugs. It has also effective 
like phenylbutazone which is used in treatment of post 
operative inflammation and arthritis. 
Cancer
 
Curcumin shows its efficiency in many types of human 
cancers such as melanoma of head and neck, breast, 
colon, pancreatic, prostate and ovarian cancers. It helps 
in targeting various levels of regulations in the 
processes of cellular growth and apoptosis. [13-24] 
The current position of curcumin‟s potential against 
various cancers is synergistically analyzed and 
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presented below under different headings. Breast cancer 
is the most common and normally diagnosed cancer in 
women. In oesophageal cancer curcumin inhibit 
cytokinin induced activation oesophageal endothelial 
cells [25, 26]. 5-Fluorouracil shows inhibition of growth of 
gastric carcinoma cells in gastric cancer. In intestinal 
cancer, in vivo studies in mouse models showed that 
curcumin is responsible for the modification of 
apoptosis resistance, leading to the inhibition of tumour 
formation and the prevention of adenoma development 
in the intestinal tract [25, 27]. 0.45-3.6 dose of curcumin 
were administered daily radiologically stable disease 
was observed in 2 out of 15 patients for up to 4 months 
of treatment [25, 26]. Curcumin shows its potential in 
many other cancers. 
 
Inspite of that it is already proved that curcumin shows 
low bioavailability. To overcome these problems, 
advanced drug delivery needs to design which gives 
good and prolonged therapeutic effect. Various drug 
delivery systems like Nanoparticles (polymeric and 
solid lipid NP, solid lipid nanoparticles), liposome 
(formulation of curcumin for parentral administration), 
microemulsion/ microencapsulation, implantable drug 
delivery systems [28, 36] can be formulated. 
 
Polymeric and solid lipid NP formulation 
Nanoparticle proved its efficiency in targeting tumors 
because of vascular leakiness due to huge production of 
cytokinines and angiogenesis cascade at these sites. In 
various tumors the permeability ranges are between 
380-780 nm but in normal it ranges from 2-4 nm. This 
large difference helps in targeting of tumors and 
accumulation of resulting enhanced permeation. Being 
lipophillic curcumin encapsulated in polymers or 
phospholipids not only enhances its bioavailability but 
also increase its stability. [28, 37-41] 
 
Curcumin as an Antioxidant
 [12] 
Free radicals can originate from environmental 
chemicals, tissue injury, infections and auto-immune 
processes. Antioxidant protects the body from damage 
from free radicals. One study showed that curcumin is 8 
times more powerful than vitamin E in preventing lipid 
per oxidation. 
 
Curcumin’s Antimicrobial Effects [12] 
Several studies in animal models showed that turmeric 
extract and curcumin inhibits the growth of a variety of 
bacteria, parasites and pathogenic fungi. Turmeric 
reduced the lesions caused by intestinal parasites, 
pathogenic fungi and various other organisms. Topical 
applications of curcumin extract were also effective. 
 
Liposomal formulation for Parenteral 
administration 
Liposomes shows greater encapsulation efficiency 
especially DMPC and DPPC of particle size 100-150 
nm which inhibit 70% -80% cellular proliferations of 
human prostate LNcaP and c4-2Bcancer cell .[28, 42-46] 
 
Micro emulsion/Microencapsulation 
Mostly carrier or technique used is micro 
emulsion/microencapsulation giving high drug 
entrapment efficiency with long term stability. These 
thermodynamically stable, transparent formulations are 
characterize by a dynamic microstructure resulting 
mixing lipophillic and hydrophilic excipients in the 
presence of suitable surfactants. This not only helps in 
delivering lipophillic compound like curcumin across 
lipophillic cell membranes but also through skin. [28, 47-51] 
 
Implantable drug delivery systems 
Implants with homogeneous entrapment of drugs in this 
type of system a polymeric matrix achieve sustained 
localized delivery showing desired bioavailability into 
systemic circulation by slowly releasing the 
encapsulated drug at the site of implantation. [28, 52-55]. 
 
PHARMACOKINETICS
 [56]
 
Asai A. & Miyazawa T. (2000) investigated the 
absorption and metabolism of orally administered 
curcuminoids (curcumin, demethoxycurcumin and 
disdemethoxycurcumin) in rats. High performance 
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liquid chromatography (HPLC) and Liquid 
Chromatography Mass Spectrometry (LS-MS) analysis 
after enzymatic hydrolysis, showed that the 
predominant metabolites in plasma following 
administration were glucuronides and glucoronide/ 
sulfates (conjugates with both glucuronide and sulfate) 
of curcuminoids. The plasma concentrations of 
conjugated curcuminoids reached a maximum one hour 
after administration. The conjugative enzyme activities 
for glucuronidation and sulfation of curcumin were 
found in liver, kidney and intestinal mucosa. There 
results indicate that orally administered curcuminoids 
are absorbed from the alimentary tract and present in the 
general blood circulation after largely being 
metabolized to the form of glucuronide and glucuronide 
/ sulfate conjugates. 
 
Various studies performed in animal models or human 
models [6, 57, 58, 59-62] proved that curcumin is extremely 
safe even at very high doses. For example, phase I 
clinical trials indicated that curcumin, when taken high 
dose as 12 g per day, is well tolerated. [6,60,62] In the same 
way, the effectiveness of curcumin in various diseases 
including cancer has also been well established  [6,63]   
Several clinical studies dealing with the efficacy of 
curcumin in humans can also be cited The 
pharmacological safety and efficacy of curcumin makes 
it a possible compound for treatment and prevention of 
a wide variety of human diseases. In spite of that the 
efficacy and safety of curcumin has not yet been 
approved as a therapeutic agent, and the relative 
bioavailability of curcumin has been highlighted as a 
major problem for this. The purpose of this review is to 
discuss in detail the bioavailability, factors controlling 
bioavailability, and means to improve the bioavailability 
of curcumin. [6, 64-65] 
 
BIOAVAILABILITY OF CURCUMIN 
The reasons for low bioavailability of any agent inside 
the body are low intrinsic activity, poor absorption, and 
high rate of metabolism, inactivation of metabolic 
products and/or rapid elimination and clearance from 
the body. There are various studies which is related to 
absorption, distribution, metabolism and excretion of 
curcumin, exposed poor absorption and rapid 
metabolism that strictly curtails its bioavailability [6, 66] 
resulting low serum levels, limited tissue distribution 
and short half-life. Regarding the distribution of 
curcumin, it showed its accumulation in the intestine, 
colon and liver, so this is   one of the major reasons why 
it is showing most promising in vivo effects in 
gastrointestinal diseases when compared with other 
organ systems. The liver, and to a lesser extent the 
intestinal mucosa are the major organs responsible for 
metabolism of curcumin. On absorption, curcumin gets 
converted into metabolite form i.e., glucuronides and 
sulfates or it is reduced to hexahydrocurcumin. To 
overcome these problems, there is no clear 
understanding whether these curcumin metabolites are 
pharmacologically as active as curcumin or whether 
these conjugates have effects that differ from those of 
curcumin [62, 67, 68] 
 
The direct studies showed the low systemic 
bioavailability in humans on taking oral dose. First 
phase I clinical trial of curcumin was done in 25 patients 
[69, 70]. In this if the first dose shows no toxicity, then the 
dose was increased to another level, but the large 
volume of the drug was unacceptable to the patients 
beyond the recommended dose. In this experiment the 
scientist reported that the serum concentration of 
curcumin usually peaked at 1–2 h after oral intake of 
curcumin and slowly declined within 12 h. Urinary 
excretion of curcumin was invisible.  [69, 71]. The original 
data prepared by Wahlstorm and Blennow showed that 
after oral administration of 1 g/kg curcumin to rats, 
more than 75% of curcumin was excreted in feces and 
small amount was detected in urine. How to improve the 
bioavailability of curcumin is also an issue. The roles of 
adjuvant [69, 62] which can block metabolic pathways of 
curcumin is one of the major means that are being used 
to improve its bioavailability. Nanoparticles, liposome, 
micelles, and phospholipids complexes are other 
promising new formulations, which appear to provide 
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longer circulation, better permeability, and resistance to 
metabolic process. [6, 62.]  
 
ROLE OF BIOEHANCERS 
There is a worldwide use of herbal medicines as 
compared to synthetic drugs. Curcumin is one of them 
but the only problem is its bioavailability as compared 
to other herbal drugs. So to increase its bioavailability 
most of the pharmaceutical industries prefer enhancers 
as a possible way. There are various natural 
bioenhancers for curcumin‟s oral bioavailability i.e. 
piperine, quercitine and epigallactocatechin-3-gallate. [72] 
 
Piperine, a known inhibitor of hepatic and intestinal 
glucuronidation, was evaluated on the bioavailability 
of curcumin in rats and healthy human volunteers. It is 
considered that if curcumin was given alone, it takes 
longer time to achieve moderate serum concentrations. 
Relatively the administration of piperine increased the 
serum concentration of curcumin in less time. Time to 
maximum was significantly increased while elimination 
half life and clearance significantly decreased, and the 
bioavailability was increased, this experiment is 
performed on rats. In humans if curcumin is given 
alone, serum levels were either undetectable or very 
low. Additional administration of piperine produced 
much higher concentrations; the increase in 
bioavailability was more as compared to rats. According 
to the scientists who performed this experiment shows 
that the bioavailability was increased 154% in rats and 
in human it is increased upto 2000%. The study shows 
that in the dosages used, piperine enhances the serum 
concentration, extent of absorption and bioavailability 
of curcumin in both rats and humans with no adverse 
effects [62]. 
 
Quercetin is a flavonoid found in citrus fruits. Quercetin 
increases drugs‟ bioavailability is from the inhibition of 
the metabolizing enzyme, CYP3A4 in the intestinal 
mucosa [73].  In case of epigallocatechin-3-gallate, it also 
works like quericitine when it is combining with 
curcumin [74]. 
ROLE OF DRUG DELIVERY SYSTEM 
The main goal of any drug delivery system is to achieve 
desired concentration of the drug in blood or tissue, 
which is therapeutically effective and non toxic for a 
prolonged period [75]. 
 
Liposome 
“A colloidal, vesicular structured composed of one or 
more lipid bilayers containing aqueous compartments 
known as liposome”. In case of conventional dosage 
form when it reaches in circulatory system achieves 
therapeutic level for short time due to metabolism and 
excretion. So therapeutic level of drug encapsulated in 
liposome is for longer period and release of drug occurs 
before metabolism and excretion. [76, 77, 78] 
The overall problem of oral bioavailability is pretty 
fascinating. Over time, there are some developed simple 
ways of increasing the bioavailability of the 
various things we eat, mostly through heating them 
and concentrating them into more potent oils and 
tinctures, this is where a closely related technology 
comes into play: encapsulation. Encapsulation slows 
down the absorption of substances and allows them to 
spend more time in our bodies, increasing 
bioavailability. In researching curcumin, there are some 
papers which describes , combination of  
some relatively simple ingredients (curcumin, modified 
starch)  in a relatively simple way to increase the oral 
bioavailability of curcumin by more than 1700 times.  
The new technique involves encapsulating substances in 
liposome [79]. Encapsulation puts the drug in shattered or 
cryptic form and thus rate of metabolism of 
encapsulated drug is less than that of free drug. This 
may be beneficial in cases where metabolic degradation 
occurs [80]. 
 
Nanoparticle 
The main aim of selecting nanoparticles as a delivery 
system is to control particle size, surface properties and 
release of pharmacologically active agents in order to 
achieve the site-specific action of the drug at the 
therapeutically optimal rate and dose regimen [81]. 
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Nanoparticle based delivery systems mainly used for 
hydrophobic agents having poor aqueous solubility such 
as curcumin. A recent study is (Bisht et al.) reported the 
application of a polymer-based nanoparticle of 
curcumin namely “nanocurcumin” with less than 100 
nm size. It was found to have similar in Vitro activity as 
that of free curcumin in pancreatic cell lines. [82]  An in 
vivo study with healthy volunteers showed the 
improved efficiency of a topical application cream 
containing curcuminoid loaded SLNs over that 
containing free curcuminoids [6,51]. Overall, nanoparticle 
based systems for curcumin delivery is still needs much 
progress in this area.  
 
Micelles 
Micelles can develop the gastrointestinal absorption of 
natural drugs, so giving higher plasma levels and lower 
kinetic elimination resulting improved bioavailability [6, 
83].Pharmacokinetic studies by Ma et al. also verified 
that a polymeric micellar curcumin gave a 60-fold 
higher biological half-life for curcumin in rats compared 
to curcumin solubilized in a mixture of DMA, PEG and 
dextrose [6,84]. 
 
Phospholipid complexes 
Complexation is another possible way for increasing the 
bioavailability of curcumin. Complex of curcumin and 
phosphotidylcholine increases the bioavailability and 
absorption also due to its ampiphillic nature of complex 
can increases water and lipid solubility. [85] 
 
Derivatives and Analogues 
The chemical structure of curcumin plays a pivotal role 
in its biological activity [6, 86]. A curcumin analogue EF-
24 was reported to be a lead compound displaying 
increased antitumor action invitro and in vivo in 
comparison to curcumin. Another analogue of curcumin   
i.e.; symmetrical 1,5- diarylpentadienone compounds 
whose aromatic rings possess two alkoxy substitutes 
were synthesized and screened for anticancer 
activity.[6,87] 
 
POTENTIAL RISKS AND SIDE EFFECTS 
Various reports proved the synergistic effect of 
curcumin with chemotherapy which shows the 
administration of (2.5% w/w) of curcumin [69] disrupt 
the antitumor action of chemotherapeutic agent such as 
cyclophosphamide in treating breast cancer. [5]. The 
major drawback of the study was very short duration (3 
days) of treatment of mice with curcumin. It has been 
reported that curcumin exhibit both antioxidant and 
prooxidant activities due to activation of opposing 
activities of it [69].  
 
Contraindications 
Restriction for the patients with bile duct obstruction, 
gallstones, and GI disorders (including stomach ulcers 
and hyperacidity disorders) should not take this 
supplement. [5] 
 
Curcumin drug interaction 
Turmeric may increase the risk of bleeding or potentiate 
the effects of warfarin or other blood thinning therapies 
[5]. 
 
RECENT ADVANCEMENT AND FUTURE 
ASPECTS 
MERIVAR is the patented complex of soy 
phospholipids obtained with the phytosome       
technology which mainly works on osteoarthritis .This 
is the first time curcumin shows efficacy at low and 
realistic dosage form. It is published by Italian 
researchers on 26th of July, 2010.in Panminerva Medica. 
[88] 
 
Development and Clinical Application of 
THERACURMIN
R 
Oral bioavailability is one of the major challenges 
which limit the clinical application of curcumin [89, 90]. 
Therefore nanoparticulation technique was used to 
develop THERACURMINR highly absorbable curcumin 
formulation that is easily dispersible in water. On 
studying absorption of THERACURMINR in rats and 
human after oral administration found that rate of 
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curcumin in blood was increased in both rats and 
human, while AUC was more than 30 fold higher in 
humans compared to that of curcumin bulk powder. [89, 
91] 
LONGVIDA
TM is the another name of curcumin it is a 
drug under clinical trials another patented complex 
obtained from natural phytosome constituents by 
Verdure Sciences company which shows efficacy at low 
and realistic dosage form. It has antioxidant, anti-
inflammatory, antiviral, antibacterial, antifungal, and 
anticancer activities. It has also a major role on 
Alzheimer disease which shows limited permeability in 
brain.  [92] 
 
Clinical Application of Curcumin:  Current status 
and future 
In future ,it will be necessary to focus  attention on the 
clinical application of curcumin in neurodegenerative 
disease ,cardio vascular disease and diabetes because  
many experiments have clarified the potential value of 
curcumin in these areas As a diet derived agent 
curcumin has no severe toxicity except for minor G.I  
side effects up to the dosage of 8gm for 3 months 
.However, curcumin has a low bioavailability, so it is 
imperative to improve the bioavailability of curcumin in 
its clinical application .[93] 
 
CONCLUSION 
In this whole subject it can be concluded that curcumin 
has the ability to stand against dreadful diseases by 
giving desired action but there is one major drawback 
which is also highlighted i.e., solubility and 
bioavailability which is a challenge for all of us. 
Various strategies has now being explored in attempts to 
improve the bioavailability of curcumin such as,  
modulation of route and medium of curcumin 
administration, blocking of metabolic pathways by 
concomitant administration with other agents, and 
structural modifications . However there are also some 
novel delivery strategies including nanoparticles, 
liposomes and defined phospholipids complexes help in 
enhancement of the bioavailability and improvement of 
its medicinal value, and application of this interesting 
molecule from Mother Nature. 
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